Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Fecal microbiota transplantation in hepatic encephalopathy: a systematic review

Research output: Contribution to journalReviewpeer-review

  1. A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Editorial: non-selective beta blockers-in and out of circulation

    Research output: Contribution to journalEditorialpeer-review

View graph of relations

Hepatic encephalopathy (HE) is a reversible neurocognitive dysfunction that ranges in severity from subclinical alterations to coma. Patients with chronic liver disease are predisposed to HE due to metabolic failure and portosystemic shunting of toxins, of which ammonia is believed to be the main toxic chemical. Fecal microbiota transplantation (FMT) may reduce ammonia synthesis by altering the gut microbiota composition to a taxon low in urease, diminish uptake of ammonia by reestablishing the integrity of the intestinal barrier and increase ammonia clearance by improving liver function. In this systematic review, we summarize the insights of the current literature examining FMT as a treatment for HE.PubMed and EMBASE were searched on 08 February 2021 using the MeSH terms 'fecal microbiota transplantation & hepatic encephalopathy' and the abbreviations 'FMT & HE'.Eight studies fulfilled our inclusion criteria, comprising two randomized clinical trials, three case reports and three rodent studies. Thirty-nine patients with HE were treated with FMT. Thirty-nine rodents received FMT in laboratory tests. FMT improved neurocognitive test results in four human studies and two rodent studies. Microbiota originating from donors was found in human recipients one year post-FMT. Readmission of patients was lower after treatment with FMT compared to standard of care.FMT may improve neurocognitive function and reduce serious adverse events in patients with HE, but the studies conducted so far have been small and their long-term follow-up is limited. Large-scale, randomized and controlled trials are needed to validate and help standardize the clinical application of FMT in cases of HE.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume56
Issue number5
Pages (from-to)560-569
Number of pages10
ISSN0036-5521
DOIs
Publication statusPublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • FMT, Fecal microbiota transplantation, HE, cirrhosis, hepatic encephalopathy, hyperammonemia

ID: 64828257